Ramucirumab: a novel antiangiogenic agent. (June 2013)

• Record Type: Journal Article
• Authors: Wadhwa, Roopma; Taketa, Takashi; Sudo, Kazuki; Blum-Murphy, Mariela; Ajani, Jaffer A
• Is Part Of: Future oncology. Volume 9:Number 6(2013)
• Page Start: 789
• Page End: 795
• Publication Date: 2013-06
• Subjects: angiogenesis -- antiangiogenesis agent -- IMC-1121B -- ramucirumab -- VEGF -- VEGFR2; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.13.68
• Languages: English
• ISSNs: 1479-6694

Abstract

Ramucirumab (IMC-1121B) is a fully humanized monoclonal antibody that binds to VEGFR2 and can inhibit angiogenesis, a quintessential mechanism for promoting tumor growth and metastasis. Several antiangiogenesis agents are already approved for cancer therapy; however, ramucirumab's selectivity for VEGFR2 makes it interesting. The selectivity of an agent can improve safety and efficacy. This article describes the mechanism of action, pharmacokinetics, safety and clinical trial results of ramucirumab with particular emphasis on gastric cancer.